At the end of the study the systolic blood pressure differed by 2.5 mm of mercury between ramipril and placebo groups and diastolic blood pressure differed by any 1 mm of mercury. The study has been interpreted as demonstrating the cardiovascular benefits of ACE-inhibition in diabetic and nondiabetic high risk patients. Also diabetic patients are sensitive to the benefits of blood pressure reduction to greater degree that might be expected from observational data alone. All intervention studies in diabetic patients seem to imply that observed differences of blood pressure for very small degree produces huge benefits in terms of macrovascular events. The reasons of such sensitivity of diabetic patients might be because of some local effects on the vessel wall or that monitoring of blood pressure in clinic situations underestimates the actual exposure to elevated blood pressure that in untreated diabetic patients may suffer.